147 related articles for article (PubMed ID: 18574651)
1. Visual disturbance comorbid with hallucination caused by voriconazole in the Japanese population.
Imataki O; Ohnishi H; Kitanaka A; Kubota Y; Ishida T; Tanaka T
Int J Hematol; 2008 Jul; 88(1):3-6. PubMed ID: 18574651
[TBL] [Abstract][Full Text] [Related]
2. Visual disturbance or central symptom like hallucination in patients treated voriconazole: report of six cases.
Kato H; Hagihara M; Hamada Y; Koizumi Y; Nishiyama N; Yamagishi Y; Matsuura K; Mikamo H
Jpn J Antibiot; 2016 Sep; 69(3):143-150. PubMed ID: 30226950
[TBL] [Abstract][Full Text] [Related]
3. An investigation of visual hallucinations associated with voriconazole administration to patients with hematological malignancies.
Sakurada H; Yasuhara K; Kato K; Asano S; Yoshida M; Yamamura M; Tachi T; Teramachi H
Pharmazie; 2016 Nov; 71(11):660-664. PubMed ID: 29441972
[TBL] [Abstract][Full Text] [Related]
4. [Case of Scedosporium apiospermum cutaneous soft tissue infection treated with voriconazole].
Konishi M; Yonekawa S; Nakagawa C; Uno K; Kasahara K; Yoshimoto E; Maeda K; Mikasa K
Kansenshogaku Zasshi; 2008 Mar; 82(2):82-5. PubMed ID: 18411765
[TBL] [Abstract][Full Text] [Related]
5. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A
J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564
[TBL] [Abstract][Full Text] [Related]
6. [Complex visual hallucinations induced by voriconazole].
Fernández-Ruiz M; López-Medrano F; Gutiérrez E; Aguado JM
Med Clin (Barc); 2009 Jun; 133(4):156-7. PubMed ID: 19540418
[No Abstract] [Full Text] [Related]
7. Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders: a prospective multicenter trial in Japan.
Koh H; Hino M; Ohta K; Iino M; Urase F; Yamaguchi M; Yamanouchi J; Usui N; Yoshida M; Tanimoto M; Ohyashiki K; Urabe A; Tamura K; Kanamaru A; Masaoka T
J Infect Chemother; 2013 Dec; 19(6):1126-34. PubMed ID: 23813092
[TBL] [Abstract][Full Text] [Related]
8. [Clinical implication of therapeutic drug monitoring on voriconazole from the aspect of the analysis for CYP2C19 gene].
Kimura M; Yamagishi Y; Kawasumi N; Hagihara M; Hasegawa T; Mikamo H
Jpn J Antibiot; 2010 Jun; 63(3):255-64. PubMed ID: 20976881
[TBL] [Abstract][Full Text] [Related]
9. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring.
Imhof A; Schaer DJ; Schanz U; Schwarz U
Swiss Med Wkly; 2006 Nov; 136(45-46):739-42. PubMed ID: 17183438
[TBL] [Abstract][Full Text] [Related]
10. Retrospective serological tests for determining the optimal blood concentration of voriconazole for treating fungal infection.
Okuda T; Okuda A; Watanabe N; Takao M; Takayanagi K
Yakugaku Zasshi; 2008 Dec; 128(12):1811-8. PubMed ID: 19043301
[TBL] [Abstract][Full Text] [Related]
11. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events.
Chu HY; Jain R; Xie H; Pottinger P; Fredricks DN
BMC Infect Dis; 2013 Feb; 13():105. PubMed ID: 23442261
[TBL] [Abstract][Full Text] [Related]
12. Intravenous voriconazole after toxic oral administration.
Alffenaar JW; van Assen S; de Monchy JG; Uges DR; Kosterink JG; van der Werf TS
Antimicrob Agents Chemother; 2010 Jun; 54(6):2741-2. PubMed ID: 20385853
[TBL] [Abstract][Full Text] [Related]
13. Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole.
Vehreschild JJ; Böhme A; Reichert D; Kiehl MG; Arenz D; Pankraz K; Kochanek M; Ullmann AJ; Cornely OA
Int J Hematol; 2008 Mar; 87(2):126-131. PubMed ID: 18288564
[TBL] [Abstract][Full Text] [Related]
14. [Hallucinosis as side effect of voriconazole].
Flox Benítez G; Rondón Fernández P; Quero Escalada M; Fernández Ballesteros A
Rev Clin Esp; 2005 Dec; 205(12):632-3. PubMed ID: 16527191
[No Abstract] [Full Text] [Related]
15. Voriconazole-induced musical hallucinations.
Agrawal AK; Sherman LK
Infection; 2004 Oct; 32(5):293-5. PubMed ID: 15624894
[TBL] [Abstract][Full Text] [Related]
16. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.
Walsh TJ; Lutsar I; Driscoll T; Dupont B; Roden M; Ghahramani P; Hodges M; Groll AH; Perfect JR
Pediatr Infect Dis J; 2002 Mar; 21(3):240-8. PubMed ID: 12005089
[TBL] [Abstract][Full Text] [Related]
17. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
[TBL] [Abstract][Full Text] [Related]
18. Persistent photopsia following course of oral voriconazole.
Kadikoy H; Barkmeier A; Peck B; Carvounis PE
J Ocul Pharmacol Ther; 2010 Aug; 26(4):387-8. PubMed ID: 20653481
[TBL] [Abstract][Full Text] [Related]
19. Long-term visual safety of voriconazole in adult patients with paracoccidioidomycosis.
Laties AM; Fraunfelder FT; Tomaszewski K; Goodrich J; Moreira AT; Sato MT; de Queiroz-Telles F
Clin Ther; 2010 Dec; 32(13):2207-17. PubMed ID: 21316537
[TBL] [Abstract][Full Text] [Related]
20. Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies.
Hoenigl M; Duettmann W; Raggam RB; Seeber K; Troppan K; Fruhwald S; Prueller F; Wagner J; Valentin T; Zollner-Schwetz I; Wölfler A; Krause R
Antimicrob Agents Chemother; 2013 Jul; 57(7):3262-7. PubMed ID: 23629724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
